Debra Silberg
Director/Board Member at Ellodi Pharmaceuticals
Profile
Debra Silberg is currently working as a Director at Ellodi Pharmaceuticals since 2023.
Prior to this, she worked as VP-Clinical Development at Shire Plc and as Chief Medical Officer at Finch Therapeutics Group, Inc. She completed her undergraduate degree from the University of Michigan and holds a doctorate degree from D'Amore-Mckim School of Business and The Wayne State University School of Medicine.
Debra Silberg active positions
| Companies | Position | Start |
|---|---|---|
Ellodi Pharmaceuticals
 Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Director/Board Member | 27/02/2023 |
Former positions of Debra Silberg
| Companies | Position | End |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Chief Tech/Sci/R&D Officer | - |
| SHIRE | Corporate Officer/Principal | - |
Training of Debra Silberg
| University of Michigan | Undergraduate Degree |
| D'Amore-Mckim School of Business | Doctorate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private companies | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Health Technology |
- Stock Market
- Insiders
- Debra Silberg
